Key facts
- It has raised $86.4M; the latest was Early Stage VC ($42.6M) in Jan 2026.
- Notable investors include Shenzhen Capital Group, Beijing State-owned Capital Operation and Management, K2VC, Shun Xi Fund, Zhongguancun Development Venture Capital Fund — 16 tracked in total.
- Status: Privately Held (backing).
Investors
16+- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for MicroCyto
- ·The full record, as it builds
Funding rounds
No funding rounds for MicroCyto are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MicroCyto
Manufacturer and Developer of biotechnology solutions intended for human and animal nutrition, and chemical materials. The company's products mainly focus on synthetic biotechnology and commit to using low-carbon, energy-saving, and sustainable methods to produce various compounds for use in medicine, daily chemicals, agriculture, food, feed, and materials, and other fields, providing customers with reliable and efficient products.
- Sector
- Materials and Resources
- HQ
- Beijing, China
- Founded
- 2021
- Employees
- 100
- Website
- microcyto.cn/
- Ownership
- Privately Held (backing)
MicroCyto doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MicroCyto shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MicroCyto in its N-PORT filings yet. We sweep new filings monthly.